Alphyn Biologics Private Investor Briefing – Virtual

Event Details

Alphyn Biologics Private Investor Briefing - Virtual

by CONNECTpreneur Investor Network

TUESDAY, February 24, 2026

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

Opus8 is hosting a small, invitation-only investor meeting featuring Alphyn Biologics, a late-clinical dermatology company entering Series B formation.

This closed-door session will provide direct access to the Alphyn management team and an opportunity to review recent clinical progress and upcoming milestones.

Company Overview

Alphyn Biologics is a late-clinical dermatology company developing patented, plant-derived topical therapeutics, led by a Phase 2a–completed asset in Atopic Dermatitis with additional pipeline programs including Molluscum Contagiosum Virus (MCV).

What Differentiates Alphyn

Huge Market – Multi-target topical mechanism addressing multiple disease drivers
Excellent Traction – Recently closed on $15 million Series A
Strong safety and tolerability profile to date
Patent protection in the U.S. and Europe extending to 2043
Secured, regulatory-compliant raw material supply

Event Details

Date: Tuesday, February 24, 2026
Time: 11 AM EST
Location: Online via Zoom

Attendance is limited and curated.

Important Notes

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

To request investor materials, contact:
Avery North — anorth@opus8.com

Event Details